How To Spot a 100% Winner
It wasn’t long ago that I highlighted Planet Labs as a stock with the potential to blast off. At the time it was sitting at $1.90 per share.
Fast forward to the present and Planet Labs has soared well above $4 per share and is now posting gains of over 100%.
So what was it that revealed the hallmarks of a stock about to pop? » Read more about: How To Spot a 100% Winner »
Read More
Crypto’s Dirty Little Secret EXPOSED
It’s popular to be on the side of crypto. It speaks to the innovative and rebellious spirit that weaves its way through generations of Americans. Crypto takes on “The Man”, fiat currency, centralized control, and ultimately Federal Reserve money printing. Yet, if crypto is the answer, why is it so reliant on fiat?
Here’s the dirty little secret of crypto exposed in plain sight.
» Read more about: Crypto’s Dirty Little Secret EXPOSED »
Read More
Genius Billionaire Investing Strategy (Buffett Inspired)
After scouring through billionaire portfolios recently, something surprising jumped out. After doing a deeper dive, the genius of the strategy became apparent. It’s similar to a strategy Buffett employed pre-2020. Before getting into what Dalio did, let’s look at Warren Buffett’s famous position, and how smart it was but also how and why it ended poorly.
» Read more about: Genius Billionaire Investing Strategy (Buffett Inspired) »
Read More
1 Spectacular SaaS Stock Taking Over the Planet
Amid the recent bear market, many renowned stocks have dipped to bargain prices, with analysts advocating for big names like Apple and Amazon. But, what about the lesser-known gems?
In the data industry, Planet Labs is shining bright. After reading this article, you may want to consider adding this Earth-imaging company to your portfolio of growth opportunities.
» Read more about: 1 Spectacular SaaS Stock Taking Over the Planet »
Read More
1 Organ Transplant Disruptor to Buy on the Dip
TransMedics (NASDAQ:TMDX) is an innovative biotechnology company that may well have the potential to disrupt the $11 billion organ transplant industry.
The company’s unique organ care system technology protects and monitors donor organs before they are transplanted into patients, resulting in improved organ health and outcomes. TransMedics also provides logistical services,
» Read more about: 1 Organ Transplant Disruptor to Buy on the Dip »
Read MoreThe Ivy
Breaking the $1 Billion Barrier, What’s Next for Security Leader?
CyberArk Software (NASDAQ: CYBR) just delivered a standout quarter, officially surpassing $1 billion in annual revenue for the first time in fiscal 2024. The identity security powerhouse—best known for its privileged access management solutions—is scaling at an impressive pace, fueled by surging demand, strategic acquisitions, and a seamless transition to a subscription-based model.
We take a deep dive into CyberArk’s latest earnings,
» Read more about: Breaking the $1 Billion Barrier, What’s Next for Security Leader? »
Read MoreThe Spotlight
Is This Space Firm Set To Blast Off
At an annual conference some years ago, a Berkshire Hathaway shareholder asked Warren Buffett how it was possible for smaller investors to rival his own performance and track record during the 1960s, which was his best period. He corrected the questioner and commented that, in fact, his best years were prior to that in the 1950s when he averaged gains closer to 50% annually.
» Read more about: Is This Space Firm Set To Blast Off »
Read MoreThe Daily
Former Apple CEO John Sculley Identifies This Company's As Apple's First Real Competitor In Decades
John Sculley, the former CEO of Apple Inc. (NASDAQ:AAPL), has identified OpenAI as major competitor to Apple in years. He also predicted that AI will lead to a shift to subscription-based business models.
Sculley Calls OpenAI Apple’s First Major Rival In Decades
At the Zeta Live conference in New York City on Thursday,